PT-141 (Bremelanotide) vs Prostamax
Side-by-side comparison of key properties, dosing, and research.
Sexual Health & Libido
PT-141 (Bremelanotide)Anti-Aging & Longevity
Prostamax- Summary
- PT-141 (Bremelanotide) is a cyclic peptide melanocortin receptor agonist that enhances sexual desire and arousal through central nervous system mechanisms. It is FDA-approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder (HSDD).
- Prostamax is a tetrapeptide bioregulator (Lys-Glu-Asp-Pro) developed by Professor Vladimir Khavinson, tissue-specific for the prostate gland. It supports prostate epithelial cell function, promotes normalization of prostate tissue, and is studied for its potential in benign prostatic hyperplasia (BPH), prostatitis, and prostate anti-aging. It is one of the more widely used Khavinson bioregulators among men over 40.
- Half-Life
- 2–3 hours
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- SubQ
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 0.5–1.75 mg
- 10 mg per day
- Frequency
- As needed (not daily)
- Daily for 10–30 days
- Key Benefits
- Enhances sexual desire and libido in both men and women
- Improves arousal through central nervous system activation
- Effective for psychological erectile dysfunction
- Works for female sexual arousal disorder
- May improve sexual satisfaction and intensity
- Fast-acting — effects within 45–60 minutes
- FDA-approved for HSDD in premenopausal women
- Supports normalization of prostate tissue architecture
- May reduce prostate enlargement associated with BPH
- Anti-inflammatory effects on prostatic tissue
- Reduces prostate cell apoptosis from oxidative stress
- Potential support in chronic prostatitis
- Anti-aging effects on prostate glandular tissue
- Complementary to conventional BPH therapies
- Side Effects
- Nausea (most common — 40% of users in clinical trials)
- Facial flushing and warmth
- Transient blood pressure changes (typically increase then normalize)
- Headache
- +2 more
- Generally well tolerated in available research
- Mild injection site reactions
- No significant adverse urological events reported at standard doses
- Stacks With
- —
- —